Statement of Changes in Beneficial Ownership (4)
03 Dezembro 2021 - 7:10PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Marguglio David J. |
2. Issuer Name and Ticker or Trading Symbol
Adamis Pharmaceuticals Corp
[
ADMP
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP and Chief Business Officer |
|
(Last)
(First)
(Middle)
C/O ADAMIS PHARMACEUTICALS CORPORATION, 11682 EL CAMINO REAL, STE 300 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/1/2021 |
|
(Street)
SAN DIEGO,, CA 92130
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 12/1/2021 | | S | | 50757 (1) | D | $0.785 (2) | 258765 (3) | D | |
| Common Stock | | | | | | | | 5884 | I | By D. Marguglio as custodian for children |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Explanation of Responses: |
| (1) | The shares were sold to pay the withholding and tax obligations relating to the issuance of shares upon the vesting of RSUs previously granted to the reporting person. |
| (2) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7784 to $0.7925, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| (3) | Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Marguglio David J.
C/O ADAMIS PHARMACEUTICALS CORPORATION
11682 EL CAMINO REAL, STE 300
SAN DIEGO,, CA 92130 | X |
| SVP and Chief Business Officer |
|
Signatures
|
| /s/ David C. Benedicto, as Attorney-in-Fact | | 12/1/2021 |
| **Signature of Reporting Person | Date |
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
